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Introduction of non-canonical amino acids into proteins is a powerful method for the
creation of macromolecules with novel properties.[1–3] In particular, 5,5,5-trifluoroleucine
(TFL, 2) has been utilized as a more hydrophobic surrogate of leucine in various contexts
(Figure 1).[4, 5] When incorporated into the hydrophobic cores of certain coiled-coil proteins,
TFL triggers an increase in stability, rendering proteins more resistant to thermal and
chemical denaturation.[6, 7] Furthermore, despite the larger volume of CF3 compared to CH3,
protein structure and activity can be retained upon replacement of leucine (Leu, 1) by
TFL.[8, 9]
Leu contains one stereocenter (Cα), which has the S-configuration. Replacement of a methyl
group by a trifluoromethyl group at Cγ introduces an additional stereocenter and yields the
two diastereoisomers (2S,4S)-5,5,5-trifluoroleucine (3) and (2S,4R)-5,5,5-trifluoroleucine
(4) (Figure 1). Here we report the effects of TFL stereochemistry on coiled-coil peptide
biosynthesis and stability. We demonstrate that both 3 and 4 are activated and incorporated
into recombinant peptides prepared in Escherichia coli. Coiled-coil homodimers of peptides
bearing 3 or 4 exhibit increased stability when compared to dimers of the Leu form of the
peptide. An equimolar mixture of the two fluorinated peptides forms a heterodimer of
modestly enhanced thermal stability relative to the homodimers.
The fidelity of translation is governed in large part by the activation of amino acids by their
cognate aminoacyl-tRNA synthetases (AARS).[10] Although some AARSs are known to
tolerate non-canonical substrates, amino acid activation can be acutely sensitive to side-
chain stereochemistry. For example, isoleucine contains two stereocenters, both of S-
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configuration: one at Cα and another at Cβ. The (2S,3R)-isomer (allo-isoleucine) is not
incorporated into proteins, although there is evidence that it is bound and activated by
isoleucyl-tRNA synthetase (IleRS).[11–14] Stereochemistry can also determine the fate of
non-canonical amino acids as possible substrates for protein synthesis in E. coli. For
instance, the isoleucine analogue, 2-amino-3-methyl-4-pentenoic acid, is accepted only in its
(2S,3S)-form, while the valine (or isoleucine) analogue, 4,4,4-trifluorovaline (TFV), is
active only in its (2S,3R)-form.[15, 16] We sought to explore whether leucyl-tRNA synthetase
(LeuRS) exhibits a stereochemical preference with respect to activation of TFL.
Coiled-coil peptides constitute simple model systems for use in investigations of protein
biosynthesis and stability.[17–20] Stereoisomers 3 and 4 were prepared (Scheme 1S,
supporting information) and evaluated for incorporation into coiled-coil peptide A1[18]
(Figure 1) in an E. coli strain auxotrophic for leucine. A1 was also expressed in media
supplemented with 1 or 2. Following purification on Ni–nitrilotriacetic acid affinity
columns, protein yields were determined to be 18 ± 4 mg/L and 9 ± 3 mg/L upon incubation
with 3 and 4, respectively, compared to 45 ± 6 mg/L for A1 prepared with 1. Peptides
containing 3 and 4 were designated SS-A1 and SR-A1, respectively.
Matrix-assisted laser desorption/ionization (MALDI) mass spectrometry analysis of A1
fragments obtained by trypsin digestion was performed to assess the extent of substitution
by 3 or 4. Fragment LKNEIEDLKAEIGDLNNTSGIR, corresponding to residues 46–67 in
A1, contains three leucine residues (shown in bold type). Fragments that correspond to
replacement at 0, 1, 2, and 3 sites by either 3 or 4 were observed (Figure 2). The expected
mass increment of 54 Da was visible for each leucine residue replaced by TFL. Incomplete
replacement of 1 most likely reflects a persistent pool of the natural amino acid replenished
by cellular protein turnover.[19] The distribution of peak intensities (though not simply
related to the relative abundances of fragments) is roughly consistent with unbiased
substitution of 3 or 4, and suggests a slight preference for incorporation of 3 (90%
replacement of Leu in SS-A1) versus 4 (82% in SR-A1). Quantitative amino acid analysis
was consistent with the MALDI results, showing 91% replacement in SS-A1 and 80% in
SR-A1.
The relative rates of activation of 1 and fluorinated analogues 2–4 by LeuRS were
determined by an in vitro ATP-PPi exchange assay. The kinetic parameters are shown in
Table 1. The relative kcat/Km values show that 3 is a slightly better substrate than 4,
consistent with the modest differences in yield and incorporation levels described above. As
expected, the apparent kcat/Km for 2 fell between the values for 3 and 4 (Table 1). The
activation rates for both 3 and 4 are within the range of rates that have been shown to
support protein synthesis in conventional hosts cultured with other non-canonical amino
acids.[21] Although a slight stereochemical preference is observed with respect to activation
of 3 vs. 4, this result stands in sharp contrast to the absolute selectivity imposed by IleRS
and ValRS in the activation of TFV, in which only the 2S,3R isomer is tolerated.[15, 16]
Furthermore, the fact that both 3 and 4 can be incorporated into proteins in E. coli is
consistent with previous work showing that hexafluoroleucine is activated by LeuRS.[21] All
of these results indicate that fluorination at either of the Cδ positions is tolerated by LeuRS.
The secondary structures of all four A1 peptides were examined by circular dichroism (CD)
spectroscopy. Because the peptides can form dimers, Leu-A1, SR-A1 and SS-A1 represent
homodimers whereas the equimolar mixture of SR-A1 and SS-A1 can form either homo- or
heterodimers. All four spectra were nearly identical at 1°C, and indicated ca. 90% helical
content in each peptide as judged from the molar ellipticity at 222 nm (Figure 3A).[22, 23]
CD provided no evidence that fluorination affects the secondary structure of A1.
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Previous studies have shown that incorporation of fluorinated amino acids into coiled-coil
peptides and α-helical bundles results in enhanced stability;[7, 8, 19, 20, 24] the extent of
stabilization varies depending on the identity of the fluorinated analogue.[19, 24] To
determine whether the stereochemistry of TFL affects the extent of stabilization of A1,
thermal denaturation was monitored by CD spectroscopy (Figure 3B). For both SR-A1 and
SS-A1, the thermal melting temperature (Tm) was 65°C, 11°C higher than that of Leu-A1
(Tm = 55°C). The equimolar mixture of SR-A1 and SS-A1 exhibited a Tm of 68°C. This
additional 3°C increase in Tm, suggested that SR-A1 and SS-A1 form heterodimers rather
than a mixture of homodimers (Table 1S, supporting information). When a mixture of the
(2S,4S)- and (2S,4R)-forms of TFL was used for expression of A1, ΔTm was 13 °C,[6] nearly
identical to that observed for equimolar mixtures of SS-A1 and RR-A1.
The results reported here demonstrate that both the SR- and SS-isomers of TFL are
incorporated into proteins expressed in E. coli; the S- isomer is activated at a slightly higher
rate by LeuRS. The higher activation rate leads to higher protein yields for SS-A1 relative to
SR-A1 and to increased levels of incorporation of the fluorinated analogue. Neither
stereoisomer appears to alter the coiled-coil structure of A1. Replacement of Leu by either
isomer enhances the thermostability of A1; the heterodimer of SS- and SR-A1 shows an
additional modest increase in stability. Experiments are underway to extend these findings
and explore more fully the influence of side-chain fluorination on protein stability.
Experimental Section
Synthesis of 3 and 4
Amino acids 3 and 4 were prepared as described previously (see supporting
information).[25–27]
Protein biosynthesis and purification
Leucine auxotrophic strain LAM1000 transformed with pREP4 (Qiagen) was used as the E.
coli host to express A1, which was encoded within pQEA1 under the control of a lac
promoter. Protein expression and purification were performed as described previously.[7]
Protein concentrations were determined via UV spectroscopy.
Protein characterization
CD data were collected on an Aviv 62DS spectropolarimeter (Lakewood, NJ) using a 1 mm
pathlength cell. Wavelength scans were taken from 195 to 250 nm, with points taken every 1
nm. Temperature scans were performed from 0–95°C in 1.5°C steps. Each plot represents an
average of 3 scans.
Activation kinetics
An N-terminal His6-LeuRS fusion was expressed and purified as previously reported.[21]
Measurement of the rates of activation of leucine and analogues was performed by an ATP-
PPi exchange assay. The assay buffer conditions were 30 mM HEPES, pH 7.4, 10 mM
MgCl2, 1 mM DTT, 2 mM ATP and 2 mM [32P]-PPi (0.5 TBq/mol). A fixed concentration
of 75 nM of His6-LeuRS was used. Depending upon the activity of the enzyme toward the
substrate, the following substrate concentrations ranges were used (1: 0.6–312.5 μM; 2, 3, 4:
6.1–6250 μM). Once the reaction was completed, the reaction mixture was quenched by
addition of 200 mM PPi, 7% w/v HClO4 and 3% activated charcoal. The charcoal was
washed twice and measured on a scintillation counter. Kinetic data were fit using non-linear
regression analysis.
Montclare et al. Page 3
Chembiochem. Author manuscript; available in PMC 2011 November 9.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
A1 peptide sequence and helical wheel diagram of the dimer in which leucines are
highlighted in bold. Structures of leucine (1) and the trifluoromethyl analogs (2–4). The
asterisk in structure 2 denotes unresolved stereochemistry at the 4-position.
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Figure 2.
MALDI mass spectra of a tryptic fragment of A1 (residues 46–67) containing 3 leucine
positions. A1 was expressed in media supplemented with either 1 (A), 3 (B), or 4 (C).
Fragments corresponding to 0, 1, 2, and 3 sites of substitution are represented as ~2442,
2497, 2551 and 2605 Da, respectively.
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Figure 3.
CD spectra of Leu-A1 (○), SR-A1 (△), SS-A1 (+), and an equimolar mixture of SR-A1 and
SS-A1 (■). A) Wavelength scan at 1 °C, 10 μM protein concentration, PBS buffer, pH 7.4.
B) Thermal denaturation (1.5 °C interval, 1 minute equilibration time, 10 second averaging
time) at 10 μM protein concentration, PBS buffer, pH 7.4.
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Table 1
Kinetic parameters for activation of 1 – 4 by E. coli LeuRS[a]
Substrate Km (μM) kcat (s−1) kcat/Km (rel)
1 16.9 ± 4.5 4.22 ± 0.35 1
2 659 ± 103 0.40 ± 0.03 1/412
3 252 ± 92 0.59 ± 0.05 1/107
4 708 ± 280 0.19 ± 0.02 1/933
[a]
Substrate 1 was used as the L-isomer; 2 as a mixture of (2S,4S), (2S,4R), (2R,4S) and (2R,4R) forms; 3 as the (2S,4S) form and 4 as the (2S, 4R)
form.
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